Methodologies in Biosimilar Product Development
1st Edition
Published on 24. September 2021
Book
Hardback
380 pages
978-0-367-89634-8 (ISBN)
Description
Methodologies for Biosimilar Product Development covers the practical and challenging issues that are commonly encountered during the development, review, and approval of a proposed biosimilar product. These practical and challenging issues include, but are not limited to the mix-up use of interval hypotheses testing (i.e., the use of TOST) and confidence interval approach, a risk/benefit assessment for non-inferiority/similarity margin, PK/PD bridging studies with multiple references, the detection of possible reference product change over time, design and analysis of biosimilar switching studies, the assessment of sensitivity index for assessment of extrapolation across indications without collecting data from those indications not under study, and the feasibility and validation of non-medical switch post-approval.
Key Features:
Reviews withdrawn draft guidance on analytical similarity assessment.
Evaluates various methods for analytical similarity evaluation based on FDA's current guidelines.
Provides a general approach for the use of n-of-1 trial design for assessment of interchangeability.
Discusses the feasibility and validity of the non-medical switch studies.
Provides innovative thinking for detection of possible reference product change over time.
This book embraces innovative thinking of design and analysis for biosimilar studies, which are required for review and approval of biosimilar regulatory submissions.
Key Features:
Reviews withdrawn draft guidance on analytical similarity assessment.
Evaluates various methods for analytical similarity evaluation based on FDA's current guidelines.
Provides a general approach for the use of n-of-1 trial design for assessment of interchangeability.
Discusses the feasibility and validity of the non-medical switch studies.
Provides innovative thinking for detection of possible reference product change over time.
This book embraces innovative thinking of design and analysis for biosimilar studies, which are required for review and approval of biosimilar regulatory submissions.
More details
Series
Language
English
Place of publication
Oxford
United Kingdom
Publishing group
Taylor & Francis Ltd
Target group
College/higher education
Illustrations
91 s/w Abbildungen, 91 s/w Zeichnungen, 100 s/w Tabellen
100 Tables, black and white; 91 Line drawings, black and white; 91 Illustrations, black and white
Dimensions
Height: 240 mm
Width: 161 mm
Thickness: 26 mm
Weight
754 gr
ISBN-13
978-0-367-89634-8 (9780367896348)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
Additional editions
Sang Joon Lee | Shein-Chung Chow
Methodologies in Biosimilar Product Development
Book
09/2023
1st Edition
Chapman & Hall/CRC
€72.40
Shipment within 10-20 days
Sang Joon Lee | Shein-Chung Chow
Methodologies in Biosimilar Product Development
E-Book
09/2021
1st Edition
Chapman & Hall/CRC
€64.49
Available for download
Sang Joon Lee | Shein-Chung Chow
Methodologies in Biosimilar Product Development
E-Book
09/2021
1st Edition
Chapman & Hall/CRC
€64.49
Available for download
Persons
Sang Joon Lee, Ph.D., is a Senior Executive Vice President at Celltrion, inc. Dr. Lee was previously an assistant Professor at the University of New Mexico School of Medicine, and a Research Associate and Statistical Analyst at The University of Texas, M.D. Anderson Cancer Center. He received the B.S. degree in Statistics from Inha University, the M.S. degree in Statistics from the Seoul National University, and the Ph.D. degree in Statistics from Texas A&M University. Dr. Lee has authored or co-authored over 100 research papers and invited papers.
Shein-Chung Chow, Ph.D., is a Professor at Duke University School of Medicine. Dr. Chow was previously the Associate Director at the Office of Biostatistics, Center for Drug Evaluation and Research, United States Food and Drug Administration (FDA). Dr. Chow has also held various positions in the pharmaceutical industry such as Vice President at Millennium, Executive Director at Covance, and Director and Department Head at Bristol-Myers Squibb. He received the B.S. degree in mathematics from East China Normal University, and the Ph.D. degree in Statistics from the University of Wisconsin-Madison. Dr. Chow has authored or co-authored over 310 methodology papers and 31 books.
Shein-Chung Chow, Ph.D., is a Professor at Duke University School of Medicine. Dr. Chow was previously the Associate Director at the Office of Biostatistics, Center for Drug Evaluation and Research, United States Food and Drug Administration (FDA). Dr. Chow has also held various positions in the pharmaceutical industry such as Vice President at Millennium, Executive Director at Covance, and Director and Department Head at Bristol-Myers Squibb. He received the B.S. degree in mathematics from East China Normal University, and the Ph.D. degree in Statistics from the University of Wisconsin-Madison. Dr. Chow has authored or co-authored over 310 methodology papers and 31 books.
Content
Preface. 1. Biosimilar Product Development. 2. CMC Consideration for Quality. 3. Quality by Design. 4. Stability Studies. 5. Two One-sided Tests Versus Confidence Interval Approach. 6. Equivalence Test with Flexible Margin. 7. mQR Method for Analytical Similarity Evaluation. 8. PK/PD Bridging Studies. 9. Clinical Strategy for Non-inferiority/Similarity Margin Selection. 10: Design and Analysis of Biosimilar Switching Studies. 11: Detection of Reference Product Change. 12. Sensitivity Analysis for Assessment of Extrapolation Across Indications. 13. Design and Analysis of Non-medical Switch. 14. Case Studies. References. Subject Index.